The blood-surface interface

Cardiopulmonary Bypass: Principles and Practice: Third Edition

Volumn , Issue , 2012, Pages 423-438

  Edmunds, L Henry ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970946782     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (210)

1. Colman RW, Clowes AW, George JN. Overview of thrombosis. In:Colman RW, Marder VJ, Clowes AW, et al. eds. Hemostasis and thrombosis, 5th ed. Philadelphia:Lippincott Williams & Wilkins, 2006:3-16.
2. Colman RW, Marder VJ, Clowes AW. Overview of coagulation, fibrinolysis and their regulation. In:Colman RW, Marder VJ, Clowes AW, et al. eds. Hemostasis and thrombosis, 5th ed. Philadelphia:Lippincott Williams & Wilkins, 2006:17-20.
3. Koster A, Yeter R, Buz S, et al. Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin:results of a pilot study. J Thorac Cardiovasc Surg 2005;129:1391-1394.
4. Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In:Warkentin TE, Greinacher A, eds. Heparin- induced thrombocytopenia. New York:Marcel Dekker Inc, 2004:437474.
5. Rubens FD, Lavalee G, Ruel MA, et al. Delayed thrombin activity with hirudin anticoagulation during prolonged cardiopulmonary bypass. Ann Thorac Surg 2005;79:334-336.
6. Koster A, Hansen R, Kuppe H, et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II:a 1- year experience in 57 patients. J Cardiothorac Vasc Anesth 2000;14:243-248.
7. Koster A, Chew D, Grundel M, et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 2003;96:383-386.
8. Tollefsen DM, Zhang L. Heparin and vascular proteoglycans. In:Colman RW, Marder VJ, Clowes AW, et al. eds. Hemostasis and thrombosis, 5th ed. Philadelphia:Lippincott Williams & Wilkins, 2006:3-5.
9. Gikakis N, Rao AK, Miyamoto S, et al. Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1998;116:1043-1051.
10. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin- antithrombin III-independent inhibitors. J Clin Invest 1990;86:385.
11. Ellison N, Edmunds LH Jr, Colman RW. Platelet aggregation following heparin and protamine administration. Anesthesiology 1978;48:65-68.
12. Khuri S, Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and increases fibrinolysis before the institution of cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-1014.
13. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87:1878-1893.
14. Pixley RA, Cassello A, De La Cadena RA, et al. Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost 1991;66:540-540.
15. Wachtfogel YT, Harpel PC, Edmunds LH Jr, et al. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor and plasmin-alpha 2- plasmin inhibitor complexes during cardiopulmonary bypass. Blood 1989;73:468-471.
16. Cavarocchi NC, Schaff HV, Orszulak TA, et al. Evidence for complement activation by protamine-heparin interaction after CPB. Surgery 1985;98:525-530.
17. Kirklin JK, Chenoweth DE, Naftel DC, et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg 1986;41:193-199.
18. Despotis GJ, Summerfield MD, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovas Surg 1994;108:1076.
19. Hardy J-F, Belisle S, Robitaille D, et al. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996;112:154-161.
20. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-2131.
21. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery:is heparin the ideal anticoagulant? Thromb Haemost 1993;70:259.
22. Boisclair MD, Lane DA, Philippou H, et al. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin Fragment F1+2. Thromb Haemost 1993;70:253.
23. Koster A, Spiess B, Chew DP, et al. Effectiveness of Bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 2004;93:356-359.
24. Lewis BE, Wallis DE, Berkowitz SD, et al. Agratroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
25. Furukawa K, Ohteki H, Hirahara K, et al. The use of Argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovas Surg 2001;122:1255-1256.
26. Edwards JT, Hamby JK, Worrall NK. Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass:heparin- induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003;75:1622-1624.
27. Helmus MN, Hubbell JA. Materials selection. Cardiovasc Pathol 1993;2:53S-71S. Suppl).
28. Gunaydin S. Emerging technologies in biocompatible surface modifying additives:quest for physiologic cardiopulmonary bypass. Curr Med Chem Cardiovasc Hematol Agents 2004;2:295-302.
29. Gourlay T, Connolly P. Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective Perfusion 2003;18:225-231.
30. Uniyal S, Brash JL. Patterns of adsorption of proteins from human plasma onto foreign surfaces. Thromb Haemost l982;47:285.
31. Ziats NP, Pankowsky DA, Tierney BP, et al. Adsorption of Hageman factor (factor XII) and other plasma proteins to biomedical polymers. J Lab Clin Med 1990;116:687.
32. Horbett TA. Principles underlying the role of adsorbed plasma proteins in blood interactions with foreign materials. Cardiovasc Pathol 1993;2:137S-148S.
33. Horbett TA. Proteins:structure, properties, and adsorption to surfaces. In:Ratner BD, Hoffman AS, Schoen FJ, et al. eds. Biomaterials science. An introduction to materials in medicine. San Diego, CA:Academic Press, 1996:133-141.
34. Walport MJ. Complement. N Engl J Med 2001;344:1058-1066; 1140-1144.
35. Ratner BD. Surface properties of materials. Characterization of biomaterial surfaces. In:Ratner BD, Hoffman AS, Schoen FJ, et al. eds. Biomaterials science. An introduction to materials in medicine. San Diego, CA:Academic Press, 1996:21-35.
36. Grunkemeier JM, Tsai WB, McFarland CD, et al. The effect of adsorbed fibrinogen, fibronectin, von Willebrand factor and vitronectin on the procoagulants state of adherent platelets. Biomaterials 2000;21:2243-2252.
37. Brash JL, Scott CF, ten Hove P, et al. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces:role of the contact and fibrinolytic systems. Blood 1988;71:932.
38. Lindon JN, McManama G, Kushner L, et al. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces? Blood 1986;68:355.
39. Munro MS, Quattrone AJ, Ellworth SR, et al. Alkyl substituted polymers with enhanced albumin affinity. Trans Am Soc Artif Org 1981;27:499-503.
40. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis. In:Colman RW, Marder VJ, Clowes AW, et al. eds. Hemostasis and thrombosis, 5th ed. Philadelphia:Lippincott Williams & Wilkins, 2006:751-759.
41. Musial J, Rucinski B, Williams JA, et al. Inhibition of platelet adhesion to surfaces of extra-corporeal circuit by disintegrins:RGD- containing peptides from viper venoms. Circulation 1990;82:261-273.
42. Tsai W-B, Grunkemeier JM, McFarland CD, et al. Platelet adhesion to polystyrene-based surfaces preadsorbed with plasma selectively depleted in fibrinogen, fibronectin, vitronectin or von Willebrand's factor. J Biomed Mater Res 2002;60:348-359.
43. Kwak D, Wu Y, Horbett TA. Fibrinogen and von Willebrand;s factor adsorption are both required for platelet adhesion from sheared suspensions to polyethylene preadsorbed with blood plasma. J Biomed Mater Res 2005;74:69-83.
44. Spiker HT, Bos R, Busscher HJ, et al. Platelet adhesion and activation on a shielded plasma gradient prepared on polyethylene. Biomaterials 2002;23:757-766.
45. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis:roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004;25(26):5681-5703.
46. Gillinov AM, Bador JM, Zehr KJ, et al. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 1993;56:847-853.
47. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg 1998;66:2135-2144.
48. Gorbet MB, Sefton MV. Leukocyte activation and leukocyte procoagulants activities following blood contact with polystyrene and PEG-immobilized polystyrene beads. JLab Clin Med 2001;137:345-355.
49. Gourlay T, Stefanou DC, Asimakopoulus G, et al. The effect of circuit surface area on CD11b (Mac-1) expression in a rat recirculation model. Artif Organs 2001;25:475-479.
50. Shen M, Horbett TA. The effects of surface chemistry and adsorbed proteins on monocytes/macrophage adhesion to chemically modified polystyrene surfaces. J Biomed Mater Res 2001;57:336-345.
51. Jenny CR, Anderson JM. Adsorbed IgG:a potent adhesive substrate for human macrophages. J Biomed Mater Res 2000;50:281-290.
52. Eriksson C, Nygren H. Adhesion receptors of polymorphonuclear granulocytes on titanium in contact with whole blood. J Lab Clin Med 2001;137:56-63.
53. Gorbet MB, Sefton MV. Complement inhibition reduces material- induced leukocyte activation with PEG modified polystyrene beads (Tentagel) but not polystyrene beads. J Biomed Mater Res 2005;74A:511-522.
54. Shen M, Garcia I, Maier RV, et al. Effects of adsorbed proteins and surface chemistry on foreign body giant cell formation, tumor necrosis factor alpha release and procoagulants activity of monocytes. J Biomed Mater Res 2004;70A:533-541.
55. Gorbet MB, Sefton MV. Material-induced tissue factor expression but not CD11b depends on the presence of platelets. J Biomed Mater Res 2003;67A:792-800.
56. Blackstone EH, Kirklin JW, Stewart RW. The damaging effects of cardiopulmonary bypass. In:Wu KK, Roxy EC, eds. Prostaglandins in clinical medicine:cardiovascular and thrombotic disorders. Chicago, IL.:Yearbook Medical Publishers Inc, 1982:355.
57. Colman RW. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 1984;73:1249.
58. Downing SW, Edmunds LH Jr. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992;54:1236.
59. Warren JS, Ward PA. Lichtman MA, Beutler E, Kipps TJ, et al. eds. The inflammatory response in Williams hematology. 7th ed. New York:McGraw-Hill, 2006:221-230.
60. Menasche P, Edmunds LH Jr. Inflammatory response. In:Cohn LH, Edmunds LH Jr, eds. Cardiac surgery in the adult, 2nd ed. New York:McGraw-Hill, 2003:349-360.
61. Roth JA, Golub SH, Cukingnan RA, et al. Cell-mediated immunity is depressed following cardiopulmonary bypass. Ann Thorac Surg 1981;31:350-356.
62. Ide H, Kakiuchi T, Furuta N, et al. The effect of cardiopulmonary bypass on T cells and their subpopulations. Ann Thorac Surg 1987;44:277-282.
63. Hisatomi K, Kobayashi A, Moriyama Y, et al. Combined suppressive effect of cardiopulmonary bypass and aging on cell-mediated immunity. J Thorac Cardiovasc Surg 1997;114:140-141.
64. Mandle R Jr, Colman RW, Kaplan AP. Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976;73:4179-4183.
65. Radcliffe R, Bagdasarian A, Colman RW, et al. Activation of bovine factor VII by Hageman factor fragments. Blood 1977;50:611-617.
66. Gikakis N, Khan MMH, Hiramatsu Y, et al. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in-vitro extracorporeal circulation. Circulation 1996;94(Suppl II):341-346.
67. Sundaram S, Gikakis N, Hack CE, et al. Nafamostat Nesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996;75:76-82.
68. Irvine L, Sundaram S, Courtney JM, et al. Monitoring of Factor XII activity and granulocyte elastase release during cardiopulmonary bypass. ASAIO Trans 1991;37:569-571.
69. Boisclair MD, Lane DA, Philippou H. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-3357.
70. Burman JF, Chung HI, Lane DA, etal. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 1994;344:1192-1193.
71. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991;266:7353-7358.
72. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman R, et al. Cell- derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997;96:3534-3541.
73. Philippou H, Adami A, Davidson SJ, et al. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost 2000;84:124-128.
74. Sturk-Maquelin KN, Nieuwland R, Romijn FP, et al. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003;1:1920-1926.
75. Hattori T, Khan MMH, Colman RW, et al. Plasma tissue factor plus activated peripheral mononuclear cells activate factors VII and X in cardiac surgical wounds. J Am Coll Cardiol 2005;46:707-713.
76. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Path 1989;134:1087-1096.
77. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor:a circulating, soluble thrombogenic protein. Nat Med 2003;4:458-462.
78. Ruf W, Rehemtulla A, Edgington TS. Phospholipid-independent and-dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991;266:2158-2166.
79. Koyama T, Nishida K, Ohdama S, et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994;87:343-347.
80. Giesen PLA, Rauch U, Bohrmann B, et al. Blood-borne tissue factor:another view of thrombosis. Proc Natl Acad Sci 1999;96:2311-2315.
81. Suefuji H, Ogawa H, Yasue H, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997;134:253-259.
82. Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999;99:2908-2913.
83. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;95:930-935.
84. Fujimi S, Ogura H, Tanaka H, et al. Increased production of leukocyte microparticles with enhanced expression of adhesion molecules from activated polymorphonuclear leukocytes in severely injured patients. J Trauma-Injury, Infect, CritCare 2003;54:114-119.
85. Shibamiya A, Tabuchi N, Chung J, et al. Formation of tissue factorbearing leukocytes during and after cardiopulmonary bypass. Thromb Haemost 2004;92:124-131.
86. Khan MMH, Hattori T, Niewiarowski S, et al. Truncated and microparticle free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII. Thromb Haemost 2006;95:462-468.
87. Stibbe J, Kluft C, Brommer EJP, et al. Enhanced fibrinoytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984;14:375.
88. Gram J, Janetzko T, Jespersen J, et al. Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increases the risk of post-surgical bleeding. Thromb Haemost 1990;63:241.
89. Levin EG, Marzec U, Anderson J, et al. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984;74:1988.
90. Marder VJ, Francis CW. Physiologic regulation of fibrinolysis. In:Colman RW, Marder VJ, Clowes AW, et al. eds. Hemostasis and thrombosis, 5th ed. Philadelphia:Lippincott Williams & Wilkins, 2006:419-436.
91. Lu H, Du-Bruit C, Soria J, et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost 1994;72:438.
92. Coughlin sR, Vu T-KH, Hung DT, et al. Characterization of a functional thrombin receptor. J Clin Invest 1992;89:351.
93. Niewiarowski S, Senui AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. J Clin Invest 1973;51:1647.
94. Rinder CA, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-1572.
95. Wenger RK, Lukasiewicz H, Mikuta BS, et al. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989;97:235-239.
96. Rinder CS, Bonnert J, Rinder HM, et al. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;74:388-393.
97. Rinder HM, Bonan JL, Rinder CS, et al. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 1991;78:1760-1769.
98. Rinder CS, Bonan JL, Rinder HM, et al. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992;79:1201-1205.
99. Chesterman CN, Berndt MC. Platelet and vessel wall interaction and the genesis of atherosclerosis. Clin Haematol 1986;15:323-353.
100. George JN, Pickett EB, Saucerman S, et al. Platelet surface glycoprotein. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects and observations in individuals during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986;78:340-348.
101. Abrams CS, Ellison N, Budzynski AZ, et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990;75:128-138.
102. Miyamoto S, Marcinkiewicz C, Edmunds LH, et al. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GPIIb/IIIa. Thromb Haemost 1998;80:225-230.
103. Hill JD, Aguilar MJ, Baranco A, et al. Neuropathological manifestations of cardiac surgery. Ann Thorac Surg 1969;7:409-419.
104. Sylivris SC, Levi G, Matalanis A, et al. Pattern and significance of cerebral microemboli during coronary artery bypass grafting. Ann Thorac Surg 1998;66:1674-1678.
105. Edmunds LH Jr, Ellison N, Colman RW, et al. Platelet function during open heart surgery:comparison of the membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982;83:805-812.
106. Salzman EW, Lindon J, Brier D. Surface-induced platelet adhesion, aggregation and release. In:Vroman L, Leonard E, eds. The behavior of blood and its components in interfaces. New York:Academic Science, 1977:114-127.
107. Addonizio VP Jr, Strauss JF III, Li-Feng C, et al. Release of lysosomal hydrolases during extracorporeal circulation. J Thor Cardiovas Surg 1982;84:28-34.
108. Zilla P, Fasol R, Groscurth P, et al. Blood platelets in cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 1989;97:379-388.
109. Videm V, Mollnes TE, Gergh K, et al. Heparin coated cardiopulmonary bypass; I biocompatibility markers and development of complications in a high risk population. J Thorac Cardiovasc Surg 1999;117:794-802.
110. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-857.
111. Elgebaly SA, Hashmi FH, Houser SL, et al. Cardiac-derived neutrophil chemotactic factors:detection in coronary sinus effluents of patients undergoing myocardial revascularization. J Thor Cardiovas Surg 1992;103:952.
112. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery. Circulation 1997;96:3542-3548.
113. Chenoweth DE, Hugli TE. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978;75:3943.
114. Chen S, Springer TA. Selectin receptor-ligand bonds:formation limited by shear rate and dissociation governed by the Bell model. Proc Natl Acad Sci USA 2001;98:950.
115. McEver RP. Perspectives series:cell adhesion in vascular biology:role in PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997;100:485.
116. Faurschou M, Borregaurd N. Neurtophil granules and secretory vesicles in inflammation. Microbes Infect 2003;5:1317.
117. Baggiolini M, Dewald B, Moser B. Inerleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994;55:97.
118. Wachtfogel YT, Kucich U, Greenplate J, et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987;69:324-330.
119. Kappelmeyer J, Bernabei A, Gikakis N, et al. Upregulation of Mac-1 surface expression on neutrophils during simulated extracorporeal circulation. J Lab Clin Med 1993;121:118-126.
120. Videm V. Heparin in clinical doses "primes' granulocytes to subsequent activation as measured by myeloperoxidase release. Scand J Immunol 1996;43:385-390.
121. Kappelmayer J, Bernabei A, Edmunds LH Jr, et al. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. CircRes 1993;72:1075-1081.
122. Enofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation and thrombin formation during cardiopulmonary bypass:a clinical study. J Thorac Cardiovasc Surg 1997;113:576.
123. Naldini A, Sower I, Bocci V, et al. Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation. J Cell Physiol 1998;77:76.
124. Faymonville ME, Deby-Dupont G, Larbuisson R, et al. Prostaglandin E2, prostacyclin, and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1986;91:858.
125. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989;9:2752-2755.
126. Wehlin L, Vedin J, Vaage J, et al. Peripheral blood monocyte activation during coronary artery by[ass grafting with or without cardiopulmonary bypass. Scand Cardiovasc J 2005;39:78-86.
127. Gessler P, Pretre R, Burki C, et al. Monocyte function-associated antigen expression during and after pediatric cardiac surgery. J Thorac Cardiovasc Surg 2005;130:54-60.
128. Stenanou DC, Asimakopoulos G, Yagnik DR, et al. Monocyte Fc gamma receptor expression in patients undergoing coronary artery bypass grafting. AnnThorac Surg 2004;77:951-955.
129. Ley K. Monocyte-platelet-endothelial interactions. In:Colman RW, Marder VJ, Clowes AW, et al. eds. Hemostasis and thrombosis, 5th ed. Philadelphia:Lippincott Williams & Wilkins, 2006:3691-3706.
130. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27.
131. Blackshear PL, Dorman FD, Steinbach JH, et al. Shear wall interaction and hemolysis. Trans Am Soc Artif Organs 1966;12:113-120.
132. Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis:basic principles and applications. ICTH- Report-Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis. Thromb Haemost 1986;55:5-35.
133. Goldsmith HL. The effects of flow and fluid mechanical stress on red cells and platelets. Trans Am Soc Artif Intern Organs 1974;20A:21-26.
134. Turitto VT, Hall CL. Mechanical factors affecting hemostasis and thrombosis. Thromb Res 1998;92:S25-S31.
135. Spijker HT, Graaff R, Boonstra PW, et al. On the influence of flow conditions and wetability on blood material interactions. Biomaterials 2003;24:4717-4727.
136. Lee WH Jr, Krumhaar D, Fonkalsrud EW, et al. Denaturation of plasma proteins as a cause of morbidity and death after intracardiac operations. Surgery 1961;50:29-39.
137. Wright ES, Sarkozy E, Dobell ARC, et al. Fat globulinemia in extracorporeal circulation. Surgery 1963;63:500-500.
138. Walpoth BH, Bowlin GL. The daunting quest for a small diameter vascular graft. Expert Rev Med Dev 2005;2:647-651.
139. Lynch JE, Clemson L, Deberry B, et al. ECMO:back where we started, again. Int J Artif Organs 2005;28(8):787-796.
140. Chang AC, McKenzie ED. Mechanical cardiopulmonary support in children and young adults:extracorporeal membrane oxygenation, ventricular assist devices, and long-term support devices. Pediatr Cardiol 2005;26(1):2-28.
141. Morris MC, Ittenbach RF, Godinez RI, et al. Risk factors for mortality in 137 pediatric cardiac intensive care unit patients managed with extracorporeal membrane oxygenation. Crit Care Med 2004;32:1061-1069.
142. Wolfson PJ. The development and use of extracorporeal membrane oxygenation in neonates. Ann Thorac Surg 2003;76(6):S2224-S2229.
143. Downard CD, Betit P, Chang RW, et al. Impact of AMICAR on hemorrhagic complications of ECMO:a ten-year review. J Pediatr Surg 2003;38(8):1212-1216.
144. Arnold P, Jackson S, Wallis J, et al. Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med 2001;27(8):1395-1400.
145. Smedira NG, Moazami N, Golding CM. Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure:survival at five years. J Thorac Cardiovasc Surg 2001;122:92-102.
146. Kolovos NS, Bratton SL, Moler FW, et al. Outcome of pediatric patients treated with extracorporeal life support after cardiac surgery. Ann Thorac Surg 2003;76:1435-1442.
147. Doll N, Kiaii B, Borger M, et al. Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock. Ann Thorac Surg 2004;77:151-157.
148. Tabuchi N, Haan J, Boonstra PW, et al. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovas Surg 1993;106:828.
149. Gorman RC, Ziats NP, Gikakis N, et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;111:1-12.
150. Muehrcke DD, McCarthy PM, Stewart FW, et al. Complications of extracorporeal life support systems using heparin-bound surfaces. J Thorac Cardiovas Surg 1995;110:843.
151. Brooker RF, Brown WR, Moody DM, et al. Cardiotomy suction:a major source of brain lipid emboli during cardiopulmonary bypass. Ann Thorac Surg 1998;65:165.
152. Kincaid EH, Jones TJ, Stump DA, et al. Processing scavenged blood with a cell saver reduces cerebral lipid microembolization. Ann Thorac Surg 2000;70:1296.
153. Albes JM, Stohr IM, Kaluza M, et al. Physiological coagulation can be maintained in extracorporeal circulation by means of shed blood separation and coating. J Thorac Cardiovasc Surg 2003;126:1504-1512.
154. De Somer F, Van Belleghem Y, Caes F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002;123:951-958.
155. Dietrich W, Spannagl M, Schramm W, et al. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;102:505.
156. Edmunds LH Jr. Hemostatic problems in surgical patients. In:Colman RW, Marder VJ, Clowes AW, et al. eds. Hemostasis and thrombosis:basic principles and clinical practice, 5th ed. Philadelphia:Lippincott Williams & Wilkins, 2006:1103-1119.
157. Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass:acquired transient platelet dysfunction associated with selective alpha granule release. Blood 1980;56:824.
158. Pifarre R, Babka R, Sullivan HJ, et al. Management of postoperative heparin rebound following cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981;81:378.
159. Blauth CI, Smith PL, Arnold JV, et al. Influence of oxygenator type on the prevalence and extent of microembolic retinal ischemia during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:61.
160. Edmunds LH Jr, Williams W. Microemboli and the use of filters during cardiopulmonary bypass. In:Utley JR, ed. Pathophysiology and techniques of cardiopulmonary bypass, Vol. II. Baltimore:Williams & Wilkins, 1983:101-114.
161. Hessel EA II, Edmunds LH Jr. Extracorporeal perfusion systems. In:Cardiac surgery in the adult. Cohn LH, Edmunds LH Jr, 2nd ed. New York McGraw-Hill, 2003:317-337.
162. Blauth CI. Macroemboli and microemboli during cardiopulmonary bypass. Ann Thorac Surg 1995;59:1300.
163. Clark RE, Magraf HW, Beauchamp RA. Fat and solid filtration in clinical perfusion. Surgery 1975;77:216.
164. Griffin S, Pugsley W, Treasure T. Microembolism during cardiopulmonary bypass:a comparison of bubble oxygenator with arterial line filter and membrane oxygenator alone. Perfusion 1991;6:99.
165. Clark RE, Brillman J, Davis DA, et al. Microemboli during coronary artery bypass grafting. J Thorac Cardiovasc Surg 1995;109:249.
166. Pugsley W, Klinger L, Paschalis C, et al. The impact of microemboli during cardiopulmonary bypass on neuropsychological functioning. Stroke 1994;25:1393.
167. Hammon JW, Edmunds LH Jr. Organ damage. In:Cohn LH, Edmunds LH Jr, eds. Cardiac surgery in the adult, 2nd ed. New York McGraw-Hill, 2003:361-388.
168. Wareing TH, Davila-Roman VG, Barzilai B, et al. Management of the severely atherosclerotic ascending aorta during cardiac operations:a strategy for detection and treatment. J Thorac Cardiovasc Surg 1992;103:453.
169. Reichenspurner H, Navia JA, Benny G, et al. Particulate embolic capture by an intra-aortic filter device during cardiac surgery. J Thorac Cardiovasc Surg 2000;119:233.
170. Cook DJ, kZehr KJ, Orszulak TA, et al. Profound reduction in brain embolization using an endoaortic baffle during bypass in swine. Ann Thorac Surg 2002;73:2002.
171. Newman MI, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary artery bypass grafting. N Engl J Med 2001;344:395.
172. Selnes OA, Grega MA, Borowicz LM Jr, et al. Cognitive outcomes three years after coronary artery bypass surgery:a comparison of on-pump coronary bypass graft surgery and nonsurgical controls. Ann Thorac Surg 2005;79:1201-1209.
173. Smith EEJ, Naftel DC, Blackstone EH, et al. Microvascular permeability after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987;94:225.
174. Bando K, Turrentine MW, Bijay P, et al. Effect of modified ultrafiltration in high risk patients undergoing operations for congenital heart disease. Ann Thorac Surg 1998;66:821-827.
175. Dijk DV, Jansen EWL, Hijman R, et al. Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery. JAMA 2002;287:1405.
176. Stallwood MI, Grayson AD, Mills K, et al. "Acute renal failure in coronary artery bypass surgery" independent effect of cardiopulmonary bypass. Ann Thorac Surg 2004;77:968-972.
177. Rinder CA, Fontes M, Mathew JP, et al. Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury. Ann Thorac Surg 2003;75:899-905.
178. Edmunds LH Jr, Stenach N. The blood-surface interface. In:Gravlee GP, Davis RF, Kurusz M, et al. eds. Cardiopulmonary bypass:principles and practice, 2nd ed. Media, Pennsylvania:Williams & Wilkins, 2000:149-166.
179. Ovrum E, Holen EA, Tangen G, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin:clinical and hemostatic effects. Ann Thorac Surg 1995;60:365.
180. te Velthuis H, Baufreton C, Jansen PG, et al. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovas Surg 1997;114:117-122.
181. Wagner WR, Johnson PC, Thompson KA, et al. Heparin-coated cardiopulmonary bypass circuits:hemostatic alterations and postoperative blood loss. Ann Thorac Surg 1994;58:734.
182. Boonstra PW, Gu YJ, Akkerman C, et al. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;107:289-292.
183. Fosse E, Thelin S, Svennevig JL, et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes :a European multicentre study. Eur J Cardiothorac Surg 1997;11:320-327.
184. Lappegard KT, Riesenfeld J, Brekke O-L, et al. Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. Ann Thorac Surg 2005;79:917-923.
185. Videm V, Mollnes TE, Bergh K, et al. Heparin coated cardiopulmonary bypass. II. Mechanisms for reduced complement activation in vivo. J Thorac Cardiovasc Surg 1999;117:803-809.
186. Sinci V, Kalaycioglu S, Gunaydin S, et al. Evaluation of heparin- coated circuits with full heparin dose strategy. Ann Thorac Cardiovasc Surg 1999;5:156.
187. Moen O, Fosse E, Dregelid E, et al. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility. Ann Thorac Surg 1996;62:1134-1140.
188. Rubens FC. Cardiopulmonary bypass technology transfer:musing of a cardiac surgeon. J Biomater Sci 2002;13:485-499.
189. De Somer R, Francois K, van Oeveren W, et al. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. EurJ Cardiothorac Surg 2000;18:602-606.
190. Gu YJ, Boonstra PW, Rijnsburger AA, et al. Cardiopulmonary bypass circuit treated with surface-modifying additives:a clinical evaluation of blood compatibility. Ann Thorac Surg 1998;65(5):1342-1347.
191. Ereth MH, Nuttall GA, Clarke SH, et al. Biocompatibility of Trillium biopassive surface-coated oxygenator versus uncoated oxygenator during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2001;15:539-541.
192. Zimmerman AK, Aebert H, Reiz A, et al. Hemocoampatibility of PMEA coated oxygenators used for extracorporeal circulation procedures. ASAIO J 2004;50:193-199.
193. Izuha H, Hattori M, Igari T, et al. Changes in platelet aggregation during cardiopulmonary bypass:comparison of poly-2- methoxyethylacrylate and heparin as a circuit coating material. J ArtifOrg 2005;8:41-46.
194. Quaniers JM, Limet RR, Defraigne J-O. Comparison of inflammatory responses after off-pump and on-pump coronary surgery using surface modifying additives circuit. Ann Thorac Surg 2006;81:1683-1690.
195. Chung JH, Gikakis N, Drake TA, et al. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996;93:2014-2018.
196. Royston D. The serine antiprotease aprotinin (Trasylol):a novel approach to reducing postoperative bleeding. Blood Coagul Fibrinolysis 1990;1:55.
197. Gallimore MJ, Fuhrer G, Heller W, et al. Augmentation of kallikrein and plasmin inhibition capacity by aprotinin using a new assay to monitor therapy. Adv Exp Med Biol 1989;247B:55-60.
198. Blauhut B, Gross C, Necek S. Effects of high-does aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958.
199. Mangano DT, Tudor IC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-365.
200. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovas Surg 1993;106:1-10.
201. Gorman JH III, Edmunds LH Jr. Blood anesthesia for cardiopulmonary bypass. J Card Surg 1995;10:270-279.
202. Suzuki Y, Malekan R, Hansen CW III, et al. Platelet anesthesia with nitric oxide with and without eptifibatide during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1999; 117:987-993.
203. Fitch JCK, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999;100:2499.
204. Li JS, Sanders SP, Perry AE, et al. Pharmacokinetics and safety of TP10, soluble complement receptor 1 in infants undergoing cardiopulmonary bypass. Am Heart J 2004;147:173-180.
205. Verrier ED, Shernan SK, Taylor KM, et al. PRIMO-CABG Investigators. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass:a randomized trial JAMA 2004;291:2319-2327.
206. Smith PK, Carrier M, Chen JC, et al. Effect of Pexelizumab in coronary artery bypass graft surgery with extended aortic crossclamp time. Ann Thorac Surg 2006;82:781-789.
207. Haverich A, Shernan SK, Levy JH, et al. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg 2006;82:486-493.
208. Lazar HL, Bokesch PM, van Lenta F, et al. TP10 Cardiac Surgery Study Group. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004;110(Suppl 1):II274-II279.
209. Shernan SK, Smith P, Verrier ED, et al. Complement activation and cardiac surgery:a novel target for improving outcomes. Ann Thorac Surg in press.
210. Sato Y, Hiramatsu Y, Homma S, et al. Phosphodiesterase type 4 inhibition of activated polymorphonuclear leukocytes in a simulated extracorporeal circulation model. J Thorac Cardiovasc Surg 2003;125:172-177.REFERENCES.